Insilico Medicine today announces positive results from two Phase I studies in Australia and China of ISM5411 (IMAGE)

InSilico Medicine

Insilico Medicine today announces positive results from two Phase I studies in Australia and China of ISM5411

Caption

A novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico’s Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory Bowel Disease (IBD).

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.